Actavis acquires Silom Medical Company

The acquisition elevates Actavis into a top-five position in the Thai generic pharmaceutical market, with leading positions in the ophthalmic and respiratory therapeutic categories and a strong cardiovascular franchise.

The company said that the transaction is expected to be immediately accretive to non-GAAP earnings in 2014.

Actavis chairman and CEO Paul Bisaro said the acquisition shows the company’s commitment to be a leading specialty pharmaceutical company in Southeast Asia, and will provide the combined business with an even more significant and united presence in the fast-growing Thai pharmaceutical market.

"Silom Medical’s diverse product portfolio and fully integrated platform, when combined with Actavis’ current local commercial activities and world-class global generics infrastructure, will provide consumers in Thailand with expanded access to a combined, larger portfolio of affordable medicines and the increased opportunity to benefit from products in development for the market," Bisaro said.

"The larger presence in Thailand will also create a foundation for Actavis’ continued expansion across the Southeast Asian region."

Currently, Actavis markets about a dozen products through local distributors in Thailand, and has around nine additional products under registration.

The acquisition is expected to result in opportunities to expand the core therapeutic areas of cardiovascular, ophthalmology and respiratory with complementary and new products.

Silom Medical’s sales channels will also be used to create opportunities in new therapeutic categories including Oncology, Women’s Health, CNS and others.

Actavis is focused in the development and manufacturing of generic, brand, branded generic, legacy brands and over-the-counter (OTC) pharmaceutical products.